OncoTarget® Myeloid68
An NGS-Based Test for Myeloid Leukemia
Fast
Available in 6-7 business days
Proven
FDA-Cleared (510k) test
Actionable
Clear insights to therapy options
What is OncoTarget® Myeloid68?
Next-Generation sequencing (NGS) performs massively parallel sequencing of genomes, allowing for the analysis of a significant number of genomic targets with a single test. Critically, NGS allows for the detection of aberrations that may only be present at very low levels, but which may have important clinical relevance for the patient’s diagnosis and prognosis.

GoPath’s MyeloidNGS68 Panel provides actionable information for improved diagnosis, prognosis, and risk stratification for myeloid malignancies including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN).
Clinical Values
of OncoTarget® Myeloid68
Clinical Utility
The majority of myeloid tumors harbor high numbers of somatic mutations, which are not inherited but created within the tumor itself. Thus, unlike germline mutations these somatic mutations are not transmitted to offspring. Somatic mutations significantly contribute to the pathogenesis, progression and prognosis of myeloid malignancies.


GoPath’s MyeloidNGS68 Panel consists of 68 genes that targets known mutations associated with acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Testing using this panel can aid in making therapy decisions, predicting prognosis, and can be used in clinical research. This is a generic and comprehensive profiling of myeloid neoplasms.
Comprehensive and Targeted Panel of Genes

ABL1, ASXL1, ASXL2, ATRX, BCOR, BCORL1, BRAF, BRINP3, CALR, CBL, CBLB, CEBPA, CSF3R, CUX1, DNMT1, DNMT3A, EED, ELANE, ETNK1, ETV6, EZH2, FLT3, GATA1, GATA2, GNAS, HNRNPK, HRAS, IDH1, IDH2, IKZF1, JAK1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MAP2K1, MPL, MYD88, NOTCH1, NPM1, NRAS, NSD1, PHF6, PRPF8, PRPF40B, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF1, SF3A1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, SUZ12, TET1, TET2, TP53, U2AF1, U2AF2, WT1, ZRSR2

Validation
Design: GoPath MyeloidNGS68 panel is designed for analyzing clinically significant genetic alterations in hematological specimens from whole blood and bone marrow. GoPath MyeloidNGS68 panel is designed to detect single nucleotide variant, small sequence deletion, insertion and duplication. GoPath MyeloidNGS68 panel is performed using GoPath Laboratory established NGS standard laboratory platforms. MyeloidNGS68 panel is designed to enrich selected genes and regions using fresh DNA and 2872 primer mixes. The assay is designed to provide efficient coverage of all coding exons of each gene in the panel. Variant calling, detections, clinical annotations of detected variants and reporting are conducted by our established clinical-grade NGS bioinformatics platform. The assay provides high density coverage of sequencing reads (≥ 300x) for all targeted coding exons of myeloid malignancy genes.

Results: The variants of known (and unknown) significance in 15 myeloid malignancies DNA from Reference Lab (referred to as ref lab) and variants of known significance in 12 myeloid malignancies DNA from GoPath Labs were included in the validation study. These variants were analyzed by 37 replicated tests. No false negative variant was observed. However, one variant reported by the ref lab and one variant reported by GoPath Labs were not confirmed by this assay. Accuracy was assessed by comparing the analysis result of NGS panel tested in GoPath Labs to the results of the same samples from the reference lab.

A total of 54 variants were analyzed and 52 variants were identified by this assay and the results are in 96.3% concordance with the confirmed results. The assay performance characteristics of sensitivity and specificity were calculated by the following formulas (Table 02):
Myeloid Leukemia Cells
Myeloid 68 detected
Assay performnce for detection of the Myeloid panel variants
98%
Ref Lab Variants
92%
GoPath Variants
97%
Total
Additional testing available
Three different tests to determine cancer risk – PROSTATENOW™ – Germline test for prostate cancer, BRCANOW® – Hereditary test for breast and ovarian cancer -LYNCHNOW® – Screening to detect lynch syndrome.
GeneticsNow®
Testing for a diagnosis, therapy and monitoring of certain blood disorders including leukemia and lymphoma.
GoPath® Labs
Whether a patient is in remission or is currently undergoing treatment, the sooner cancer recurrence or metastasis is found, the sooner the patient can receive appropriate therapy and treatment.
OncoTracking™
Delivering the broadest, FDA-cleared Comprehensive Genomic Profiling for solid tumors.
OncoTarget®
Begin your journey- our team is ready to get you started.
Get in touch
About us
Individuals
Providers
Resources
Contact
Call us: (855) 467-2849
Email: contact@gopathlabs.com

Address: 1000 Corporate Grove Dr,
Buffalo Grove, IL, 60089

Business Hours
Monday – Friday: 8:00am-5:00pm
Saturday – Sunday – Closed
© GoPath Global, Inc. 2022 All rights reserved
Terms of use
Privacy Policy